This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

McKesson Announces New President Of U.S. Pharmaceutical Business

McKesson Corporation (NYSE: MCK) today announced that Mark Walchirk has been named president, McKesson U.S. Pharmaceutical, effective immediately. Walchirk, who was most recently chief operating officer of McKesson Specialty Health, has held numerous leadership roles at McKesson for the last 11 years, including chief operating officer of McKesson U.S. Pharmaceutical. Walchirk succeeds Brian Tyler, who was recently appointed executive vice president of corporate strategy and business development, McKesson Corporation.

Walchirk will report to Paul Julian, executive vice president and group president, McKesson Corporation. He will oversee McKesson’s largest business, which supplies branded, generic and over-the-counter pharmaceuticals and value-added business, clinical and connectivity solutions to more than 40,000 customers, including retail chains, independent retail pharmacies, hospitals, health systems, integrated delivery networks and long-term care providers.

“With past roles as chief operating officer of McKesson U.S. Pharmaceutical and McKesson Specialty Health, Mark Walchirk has deep leadership experience in our pharmaceutical distribution business and a proven track record of delivering results for our customers,” said Paul Julian, executive vice president and group president, McKesson Corporation. “Mark’s significant experience coupled with his commitment to operational excellence and our customers’ success make him the ideal choice to lead McKesson U.S. Pharmaceutical.”

Walchirk joined McKesson in 2001 and spent more than eight years in progressive leadership roles within McKesson’s U.S. Pharmaceutical business before being appointed president of McKesson Specialty Care Solutions in 2009. He led McKesson’s integration of US Oncology and assumed the role of chief operating officer for the newly combined organization, McKesson Specialty Health. In this role, he helped lead the business to record growth and introduce new solutions that empower the community patient care delivery system.

As senior vice president and chief operating officer of McKesson U.S. Pharmaceutical, Walchirk led the integration of regional distributors D&K Healthcare and McQueary Bros., contributed to the dramatic growth of McKesson’s Health Mart franchise, led the expansion of McKesson’s pharmaceutical distribution business in the institutional market, and guided McKesson to industry-leading levels of accuracy and efficiency across the company’s nationwide distribution network.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.06 -0.60%
FB $118.00 -0.05%
GOOG $698.16 0.35%
TSLA $214.45 -3.60%
YHOO $36.99 2.80%


Chart of I:DJI
DOW 17,724.54 +73.28 0.42%
S&P 500 2,058.78 +7.66 0.37%
NASDAQ 4,738.4560 +12.8170 0.27%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs